CureApp Announces Results from World’s First Randomized Control Study for Digital Therapeutic Smoking Cessation App
Tokyo, Japan – May 30, 2019 – Results from the world’s first randomized control study to examine digital therapeutic smoking cessation programs were presented on May 20 th at the American Thoracic Society International Conference. The findings demonstrate that CureApp’s nicotine dependence treatment app resulted in an improvement in continuous abstinence rate (CAR) compared to a control group over multiple time points. Kohta Satake, M.D., M.B.A., M.P.H., Chief Executive Officer of CureApp, Inc. and a respiratory specialized physician says, "Healthcare professionals are challenged to help patients fight against the psychological nicotine addiction alone between clinical visits . CureApp’s digital therapeutics approach is a breakthrough in bridging the gap between clinical visits providing daily support to the patients. We are striving for regulatory and reimbursement approval to deliver the solution as soon as possible